No profile data available.
Harvard Bioscience, Inc. (HBIO) is a healthcare company in the various healthcare equipment manufacturing industry, based in Holliston, United States, with about 316 full-time employees.
It reported revenue of $86.55 million for fiscal year 2025, down 8.1% from fiscal year 2024, and net income of -$56.70 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $20.76 million, down 4.7% from a year before. United States was its largest region in fiscal year 2025, with 45% of revenue. Its market capitalization was $37.51 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Harvard Bioscience reported $86.55 million in revenue for fiscal year 2025, down 8.1% from $94.14 million in fiscal year 2024. In Q1 2026 revenue was $20.76 million.
United States: 45% of revenue by region in fiscal year 2025, followed by Europe, Middle East and Africa (31%).
$37.51 million as of October 9, 2026.
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include MiMedx Group, Inc. (MDXG), AngioDynamics, Inc. (ANGO), Profound Medical Corp. (PROF), Elutia Inc. (ELUT).